• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Gelesis Holdings Inc. (Amendment)

    2/13/23 4:02:03 PM ET
    $GLS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GLS alert in real time by email
    SC 13G/A 1 d446457dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Gelesis Holdings Inc

    (Name of Issuer)

    Common stock, $0.0001 par value per share

    (Title of Class of Securities)

    36850R204

    (CUSIP Number)

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    SCHEDULE 13G

     

    CUSIP No.    36850R204

     

     

      1  

      Names of Reporting Persons

     

      Periscope Capital Inc.

      2  

      Check the appropriate box if a member of a Group (see instructions)

     

      (a)  ☐        (b)  ☒

      3  

      Sec Use Only

     

      4  

      Citizenship or Place of Organization

     

      Canada

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5    

      Sole Voting Power

     

       6  

      Shared Voting Power

     

      0

       7  

      Sole Dispositive Power

     

       8  

      Shared Dispositive Power

     

      0

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

      ☐

    11  

      Percent of class represented by amount in row (9)

     

      0.00%

    12  

      Type of Reporting Person (See Instructions)

     

      FI

     

    Page 2 of 5


    Item 1.

     

    (a)

    Name of Issuer:

    Gelesis Holdings Inc

     

    (b)

    Address of Issuer’s Principal Executive Offices:

    501 Boylston Street, Suite 6102, Boston, MA 02116

     

    Item 2.

     

    (a)

    Name of Person Filing:

    This Schedule 13G is being filed on behalf of Periscope Capital Inc. (“Periscope”) with respect to the shares of Common stock, $0.0001 par value per share (the “Common Stock”), of Gelesis Holdings Inc, a Delaware corporation (the “Issuer”).

    Periscope, which is the beneficial owner of 0 shares of Common Stock, acts as investment manager of, and exercises investment discretion with respect to, certain private investment funds (each, a “Periscope Fund”) that collectively directly own 0 shares of Common Stock.

    The filing of this statement should not be construed as an admission that Periscope is, for the purpose of Section 13 of the Act, the beneficial owner of the Common Stock owned by the Periscope Funds.

     

    (b)

    Address of Principal Business Office or, if None, Residence:

    333 Bay Street, Suite 1240, Toronto, Ontario, Canada M5H 2R2

     

    (c)

    Citizenship:

    See Row 4 of the Cover Page.

     

    (d)

    Title and Class of Securities:

    Common stock, $0.0001 par value per share

     

    (e)

    CUSIP No.:

    36850R204

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

           (a)    ☐    Broker or dealer registered under Section 15 of the Act;
      (b)    ☐    Bank as defined in Section 3(a)(6) of the Act;
      (c)    ☐    Insurance company as defined in Section 3(a)(19) of the Act;
      (d)    ☐    Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e)    ☐    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f)    ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
      (g)    ☐    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
      (j)    ☒    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
      (k)    ☐    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

     

    Page 3 of 5


    If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Non-U.S. investment adviser.

     

    Item 4.

    Ownership

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the Cover Page and is incorporated herein by reference.

    Periscope expressly declares that this filing shall not be construed as an admission that it is, for the purposes of Sections 13(d) or 13(g) of the Act, the beneficial owner of the securities owned by the Periscope Funds.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☒.

     

    Item 6.

    Ownership of more than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

    Not applicable.

     

    Item 8.

    Identification and classification of members of the group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    Page 4 of 5


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 13, 2023

     

    PERISCOPE CAPITAL INC.
    By:   /s/ Lisa Shostack
    Lisa Shostack, General Counsel

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

     

    Page 5 of 5

    Get the next $GLS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GLS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Puretech Health Plc

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      9/21/23 4:30:07 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Puretech Health Plc

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      6/14/23 4:30:15 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Puretech Health Plc

      4 - GELESIS HOLDINGS, INC. (0001805087) (Issuer)

      5/31/23 5:30:09 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

      MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

      4/3/23 4:05:00 PM ET
      $GLS
      $PEAR
      $SGHT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Computer Software: Prepackaged Software
      Technology
    • Gelesis Reports Fourth Quarter and Full Year 2022 Results

       Gelesis has demonstrated strong demand for Plenity, helping over 200,000 people on their weight loss journeys since launch Company has filed with FDA to make Plenity available to Over the Counter (OTC), which should significantly broaden consumer access and reduce the cost to reach new members Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity for weight management, today reported financial results for the year ended December 31, 2022. Plenity is a novel orally administered, FDA-cleared weight management therapy that helps people feel satisfied with smaller portions, so they can eat less and lose weight, while still enjoying the foods they love. Plenity

      3/28/23 7:00:00 AM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gelesis to Participate in the 25th Annual ICR Conference

      Gelesis (NYSE:GLS), the maker of Plenity for weight management, today announced that the Company will participate in the 25th Annual ICR Conference in Orlando, Florida on Monday, January 9, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005182/en/Gelesis is the maker of Plenity, an FDA-cleared weight management product. (Graphic: Business Wire) Gelesis will host a presentation at 1:30 p.m. ET. The live webcast can be accessed on the "Events & Presentations" section of the Gelesis Investor Relations website at https://ir.gelesis.com/. The webcast will also be archived and available for replay. About Gelesis Gelesis H

      1/5/23 7:00:00 AM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLS
    SEC Filings

    See more
    • Gelesis Holdings Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update, Financial Statements and Exhibits

      8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)

      10/30/23 8:58:39 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form CT ORDER filed by Gelesis Holdings Inc.

      CT ORDER - GELESIS HOLDINGS, INC. (0001805087) (Filer)

      10/19/23 2:14:03 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gelesis Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - GELESIS HOLDINGS, INC. (0001805087) (Filer)

      10/16/23 4:15:09 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLS
    Leadership Updates

    Live Leadership Updates

    See more
    • Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

      MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov

      4/3/23 4:05:00 PM ET
      $GLS
      $PEAR
      $SGHT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Computer Software: Prepackaged Software
      Technology

    $GLS
    Financials

    Live finance-specific insights

    See more
    • Gelesis Reports Fourth Quarter and Full Year 2022 Results

       Gelesis has demonstrated strong demand for Plenity, helping over 200,000 people on their weight loss journeys since launch Company has filed with FDA to make Plenity available to Over the Counter (OTC), which should significantly broaden consumer access and reduce the cost to reach new members Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity for weight management, today reported financial results for the year ended December 31, 2022. Plenity is a novel orally administered, FDA-cleared weight management therapy that helps people feel satisfied with smaller portions, so they can eat less and lose weight, while still enjoying the foods they love. Plenity

      3/28/23 7:00:00 AM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gelesis Reports Third Quarter 2022 Results

      Plenity quarterly product revenue increased 114% year-over-year to $6.4 million, with 23,500 new members and 92,000 units sold in Q3 Quarterly gross profit increased by $2.6 million year-over-year, with gross margin improving from 8% to 44% Company is preparing to submit Plenity for Over the Counter (OTC) status, which would make it available without the need for a prescription and further reduce cost of customer acquisition Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity for weight management, today reported financial results for the third quarter of 2022. Plenity is a novel orally administered, FDA-cleared weight management therapy that helps people

      11/14/22 7:00:00 AM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022

      Gelesis Holdings, Inc. (NYSE:GLS) ("Gelesis" or the "Company"), the maker of Plenity® for weight management, today announced that the Company will report financial results for the third quarter ended September 30, 2022, on November 14, 2022 prior to the market open. Gelesis management will host a live conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221107005166/en/Gelesis is a consumer-centered biotherapeutics company and the maker of Plenity for weight management. (Photo: Business Wire) The live call can be accessed via webcast on the "Events & Pr

      11/7/22 7:00:00 AM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Gelesis Holdings Inc. (Amendment)

      SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

      10/16/23 4:31:26 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Gelesis Holdings Inc. (Amendment)

      SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

      9/21/23 4:30:30 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Gelesis Holdings Inc. (Amendment)

      SC 13D/A - GELESIS HOLDINGS, INC. (0001805087) (Subject)

      6/29/23 4:30:27 PM ET
      $GLS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care